Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Leukemia 1

Interventions

Cyclophosphamide 328Methotrexate 182Cytarabine 164fludarabine phosphate 151Vincristine 128Dexamethasone 126fludarabine 123Peripheral Blood Stem Cell Transplantation 116Whole-Body Irradiation 108Etoposide 106Mycophenolic Acid 105Tacrolimus 95Busulfan 95Filgrastim 93Melphalan 81Cyclosporine 80Rituximab 79Doxorubicin 79Mercaptopurine 69Radiotherapy 62Antilymphocyte Serum 62Granulocyte Colony-Stimulating Factor 57Prednisone 56blinatumomab 55pegaspargase 54Asparaginase 54Thiotepa 52Daunorubicin 52Calcium Dobesilate 47Clofarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Precursor Cell Lymphoblastic Leukemia-Lymphoma × quizartinib × Clear all
NCT01411267 2022-04-04

AC220 for Children With Relapsed/Refractory ALL or AML

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Completed
24 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡